With Biosimilar Statistical Guidance Withdrawn, Expect Sponsor-Specific Advice, FDA's Christl Says
Executive Summary
US FDA's biosimilar chief tells Pink Sheet that sponsors will receive more advice specific to their development programs based on their data package, a practice already in use in some cases.
You may also be interested in...
US FDA's Biosimilars Chief Leah Christl Plans Departure
A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'